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The clinical efficacy of chemotherapy relies in part on its ability to potentiate anti-tumor immune responses. Recent work
shows that several chemotherapeutic drugs induce intra-tumoral expression of lymphocyte-attracting chemokines,
leading to clinical responses. Here, we argue that such knowledge should be used to screen for novel anti-tumor
treatments.
Currently approved chemotherapeutic
drugs are initially screened in vitro for
their capacity to induce cell death in
cancer cell lines. Before being used in
patients, these drugs have to be tested
in various preclinical models and in
lengthy and costly human trials to dem-
onstrate a clinical benefit. Unfortunately,
the rate of new drug failure at the clinical
stage is very high: the attrition rate of
drugs developed by large pharmaceutical
companies has recently been estimated at
around 93%.
1 Very few drugs initially
showing promising activity in vitro are
eventually approved, illustrating the short-
falls of the current cell line assays and
preclinical models. We must seek some-
thing better.
Tumors are not only made of cancer
cells; the role of the stroma in tumor
growth and metastasis is well known. In
particular, the importance of the immune
microenvironment is increasingly recog-
nized.
2 The nature, number, localization
and polarization of immune cells infiltrat-
ing human tumors are among the stron-
gest predictors of patient survival. Immune
cells are involved in many steps of cancer
progression including tumor growth, inva-
sion, dissemination and colonization of
distant organs. For example, defined sub-
sets of tumor-associated macrophages
produce growth factors and promote
angiogenesis.
3 Myeloid-derived suppressor
cells (MDSC) prevent T-cell activation
and induce epithelial-mesenchymal trans-
ition, thereby favoring growth of the
primary tumor and facilitating cancer cell
dissemination.
4 Immune cells also play a
major role in controlling cancer progres-
sion by inducing cancer cell death or
favoring tumor dormancy.
2 It is therefore
not unexpected that the ability of drugs to
control cancer progression in patients
relies, in part, on their effect on immune
cells. Unfortunately this aspect is not
addressed in the in vitro assays or xeno-
graft models commonly used to screen
chemotherapeutic drugs.
Until recently, the prevalent view was
that chemotherapy merely blunts the
immune response. Indeed, most chemo-
therapies do induce bone marrow deple-
tion;
5 tamoxifen, cisplatin, carboplatin or
temozolomide induce leucopenia and/or
thrombocytopenia. But recent data also
revealed that chemotherapies can have
beneficial effects on the anti-tumor
immune response. First, chemotherapeutic
drugs can potentiate the induction of an
immune response.
6 Low doses of cyclo-
phosphamide deplete or inhibit regulatory
T cells (Treg), while gemcitabine or 5-
fluorouacyl selectively eliminate MDSC.
Some chemotherapeutic drugs induce
immunogenic death, a process in which
debris from dying cancer cells is captured
by dendritic cells which stimulate the
induction of an anti-tumor immune
response. Second, some drugs improve
lymphocyte effector functions and act in
synergy with immune cells, making cancer
cells more sensitive to immune effectors.
For example, genotoxic drugs trigger the
DNA-damage response and augment
NKG2D ligand expression, which facili-
tates cancer cell recognition by NK and
T cells.
7
We recently uncovered a third extrinsic
mode of action of chemotherapy (Fig.1).
In melanoma patients, dacarbazine induced
intra-tumoral expression of T and NK cell-
attracting chemokines (CXCL9, CXCL10
and CCL5).
8 While before treatment,
immune effectors largely ignored cuta-
neous tumors, a significant lymphocytic
infiltrate was observed in the cutaneous
tumors after chemotherapy. Importantly,
t h i sw a so n l yo b s e r v e di nt u m o r sr e s p o n d -
ing to the treatment. No chemokine
expression was induced by dacarbazine in
chemotherapy-resistant tumors. Moreover,
patients in whom dacarbazine induced
increased expression of these chemokines
survived longer. Experiments performed
in mice showed that CXCR3, the recep-
tor for CXCL9 and CXCL10 expressed
on circulating effector T cells, was
required for chemotherapy-induced infil-
tration of T cells. In vitro experiments
confirmed that several chemotherapeutic
drugs induced expression of CXCL9,
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2CXCL10 and CCL5 in many cancer cell
lines.
It may seem paradoxical for cancer cells
to express chemokines that attract cancer
cell-killing lymphocytes. However, chemo-
kine expression is probably a physiologi-
cal response of normal cells to stress. This
interpretation is confirmed by our recent
finding that intra-tumoral expression of
CXCR3 ligands and CCL5 in hepato-
cellular carcinoma (HCC) samples corre-
lates with higher infiltration of T and NK
cells and prolonged patient survival.
9 In
fact, normal hepatocytes do express these
chemokines in response to inflammation.
Therefore, the beneficial effects of
chemotherapies are, in part, linked to their
action on immune cells, and this situation
is not unique to conventional chemother-
apy. Imatinib mesylate (Gleevec) was
initially approved in 2001 for its capacity
to inhibit the tyrosine kinase BCR-ABL
in chronic myeloid leukemia (CML).
Gleevec was later found to inhibit another
tyrosine kinase, c-kit. Because the vast
majority of gastrointestinal stromal tumors
(GIST) contain an activating KIT muta-
tion, this drug was then used in GIST. But
a recent study showed that Gleevec’s
efficacy in GIST relates primarily to its
capacity to inhibit the immunosuppres-
sive enzyme indoleamine 2,3-dioxygenase
(Ido) and thereby to potentiate T cell
responses.
10
We are just starting to understand how
drugs work in cancer patients. Clearly,
the biological events leading to clinical
responses in patients often differ from the
mechanisms for which the drug was initi-
ally selected and developed. It is essential
to incorporate this knowledge in the assays
used to screen new drugs. In particular, we
should develop assays aimed at identifying
which drugs act on the immune system
and favor immune cell trafficking to the
tumor. It would also be useful to test
currently approved drugs in such assays.
Better assays would increase the chance of
success in clinical developments.
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Figure 1. Newly discovered mode of action of chemotherapy. Chemotherapy induces melanoma
cells to express chemokines (CXCL9, CXCL10 and CCL5) that attract CD4 and CD8 T cells. T cell
infiltration into the tumor slows down cancer progression and prolongs patient survival.
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